Free Trial
NASDAQ:BPTH

Bio-Path (BPTH) Stock Price, News & Analysis

Bio-Path logo
$0.85 -0.03 (-3.73%)
(As of 11:07 AM ET)

About Bio-Path Stock (NASDAQ:BPTH)

Key Stats

Today's Range
$0.85
$0.88
50-Day Range
$0.85
$1.19
52-Week Range
$0.80
$12.40
Volume
20,940 shs
Average Volume
1.14 million shs
Market Capitalization
$2.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00
Consensus Rating
Buy

Company Overview

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Bio-Path Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
63rd Percentile Overall Score

BPTH MarketRank™: 

Bio-Path scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bio-Path has received no research coverage in the past 90 days.

  • Read more about Bio-Path's stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Path are expected to grow in the coming year, from ($6.20) to ($4.04) per share.

  • Price to Book Value per Share Ratio

    Bio-Path has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bio-Path's valuation and earnings.
  • Percentage of Shares Shorted

    2.10% of the float of Bio-Path has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Path has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Path has recently decreased by 79.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bio-Path does not currently pay a dividend.

  • Dividend Growth

    Bio-Path does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.10% of the float of Bio-Path has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Path has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Path has recently decreased by 79.98%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bio-Path has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Bio-Path this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Path insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.72% of the stock of Bio-Path is held by insiders.

  • Percentage Held by Institutions

    Only 5.74% of the stock of Bio-Path is held by institutions.

  • Read more about Bio-Path's insider trading history.
Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Stock News Headlines

StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)
Post-Election Bitcoin Warning
According to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months...
See More Headlines

BPTH Stock Analysis - Frequently Asked Questions

Bio-Path's stock was trading at $9.26 at the beginning of the year. Since then, BPTH stock has decreased by 90.8% and is now trading at $0.8510.
View the best growth stocks for 2024 here
.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Thursday, August, 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts' consensus estimates of ($1.54) by $0.38.

Shares of Bio-Path reverse split on Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), Micron Technology (MU), Anavex Life Sciences (AVXL) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
8/15/2024
Today
11/13/2024
Next Earnings (Confirmed)
11/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BPTH
Fax
N/A
Employees
10
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$20.00
High Stock Price Target
$20.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+2,162.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-16,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.71 per share

Miscellaneous

Free Float
2,534,000
Market Cap
$2.25 million
Optionable
Optionable
Beta
0.22

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:BPTH) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners